Submit a comment

Immunologic Studies in von Willebrand's Disease: EVIDENCE THAT THE ANTIHEMOPHILIC FACTOR (AHF) PRODUCED AFTER TRANSFUSIONS LACKS AN ANTIGEN ASSOCIATED WITH NORMAL AHF AND THE INACTIVE MATERIAL PRODUCED BY PATIENTS WITH CLASSIC HEMOPHILIA
Bruce Bennett, … , Oscar D. Ratnoff, Jack Levin
Bruce Bennett, … , Oscar D. Ratnoff, Jack Levin
Published October 1, 1972
Citation Information: J Clin Invest. 1972;51(10):2597-2601. https://doi.org/10.1172/JCI107077.
View: Text | PDF

Immunologic Studies in von Willebrand's Disease: EVIDENCE THAT THE ANTIHEMOPHILIC FACTOR (AHF) PRODUCED AFTER TRANSFUSIONS LACKS AN ANTIGEN ASSOCIATED WITH NORMAL AHF AND THE INACTIVE MATERIAL PRODUCED BY PATIENTS WITH CLASSIC HEMOPHILIA

Abstract

Antihemophilic globulin (AHF, factor VIII) levels were measured by a standard coagulation assay and by an immunological technique before and serially after infusion of fresh frozen plasma or cryoprecipitate into patients with von Willebrand's disease. Initial levels of AHF, measured both as procoagulant and as antigen, were low. Immediately after transfusions, the rise in levels of AHF-like antigen was compatible with the quantity of antigen present in the infused plasma or cryoprecipitate. Thereafter, levels of antigen declined rapidly and reached preinfusion values in approximately 24 hr. In contrast, procoagulant activity remained elevated, and sometimes continued to rise, for longer periods of time. One possible explanation of this finding is that the AHF molecule produced by patients with von Willebrand's disease, in response to transfusion of as yet unidentified factors, lacks the antigenic site associated with the normal AHF molecule or the inactive molecule produced by patients with hemophilia A.

Authors

Bruce Bennett, Oscar D. Ratnoff, Jack Levin

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required